Rallybio Corp RLYB
Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026
Rallybio Corp (RLYB) is a healthcare company listed in the US with a market value of about $88M. In the twelve months to September 30, 2026 it had revenue of $434000 and net income of $27M, a net margin of 6177.4%.
Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is financial health (4/5); the weakest is track record (0/5).
Key numbers: a P/E of 3.4, a price to free cash flow of 2.8, a 5-year average ROIC of -59%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 54% below the current price.
About Rallybio
Rallybio is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. It was profitable in 0 of the last 6 years in our data. Its share count rose by 42% over three years (dilution for shareholders). It spends 2284% of revenue on research and development.
Score: 2.0 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Positive free cash flow
Checks not passed
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $434000 | $858000 | $636000 | — | — | — | — |
| Net income | $27M | -$9M | -$58M | -$75M | -$67M | -$47M | -$26M |
| Free cash flow | $31M | — | -$49M | -$60M | -$57M | -$46M | -$22M |
| EPS (diluted) | $4.56 | $-1.59 | $-10.61 | $-14.72 | $-16.72 | $-14.72 | $-12.16 |
| Net margin | 6177.4% | -1046.4% | -9084.1% | — | — | — | — |
| ROIC | — | -56.9% | -97.9% | -74.1% | -40.0% | -25.9% | -18.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Rallybio’s P/E ratio?
About 3.4, based on the last twelve months of diluted earnings per share.
Is Rallybio stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 54% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Rallybio pay a dividend?
Not currently.
Is Rallybio a good stock to buy?
We do not give buy or sell advice. Rallybio scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.